During the corresponding time, Heron Therapeutics Inc recorded a revenue increase by 3.64 % year on year, sequentially revenue grew by 10.55 %. While revenue at the Heron Therapeutics Inc 's corporate clients
Heron Therapeutics Inc's Comment on Sales, Marketing and Customers
The company's products are distributed in the United States through specialty distributors and full-line wholesalers to healthcare providers and hospitals. Its product portfolio competes in the postoperative pain management market, the prevention of postoperative nausea and vomiting (PONV), and the prevention of chemotherapy-induced nausea and vomiting (CINV). Competitors and their products include MARCAINETM (Pfizer Inc.), NAROPIN® (Fresenius Kabi USA, LLC), EXPAREL® (Pacira BioSciences, Inc.), XARACOLL® and POSIMIR® (Innocoll Pharmaceuticals Limited), ANJESO® (Baudax Bio, Inc.), OFIRMEV® (Mallinckrodt Pharmaceuticals), SEGLENTIS® (Kowa Pharmaceuticals America, Inc.), BARHEMSYS® (Eagle Pharmaceuticals, Inc.), TAK-951 (Takeda Pharmaceutical Company Limited), EMEND® IV and EMEND® (Merck & Co., Inc.), AKYNZEO® (Helsinn Therapeutics (U.S.), Inc.), VARUBI® (TerSera Therapeutics LLC), and FOCINVEZTM (Amneal Pharmaceuticals, LLC). The company serves markets including postoperative pain management, PONV prevention, and CINV prevention. Customers and market participants referenced include Amneal Pharmaceuticals, LLC; Baudax Bio, Inc.; Durect Corporation; Eagle Pharmaceuticals, Inc.; Fresenius Kabi USA, LLC; Helsinn Therapeutics (U.S.), Inc.; Innocoll Pharmaceuticals Limited; Kowa Pharmaceuticals America, Inc.; Mallinckrodt Pharmaceuticals; Merck & Co., Inc.; Pacira BioSciences, Inc.; Pfizer Inc.; Takeda Pharmaceutical Company Limited; and TerSera Therapeutics LLC.
Heron Therapeutics Inc’s Comment on Sales, Marketing and Customers
The company's products are distributed in the United States through specialty distributors and full-line wholesalers to healthcare providers and hospitals. Its product portfolio competes in the postoperative pain management market, the prevention of postoperative nausea and vomiting (PONV), and the prevention of chemotherapy-induced nausea and vomiting (CINV). Competitors and their products include MARCAINETM (Pfizer Inc.), NAROPIN® (Fresenius Kabi USA, LLC), EXPAREL® (Pacira BioSciences, Inc.), XARACOLL® and POSIMIR® (Innocoll Pharmaceuticals Limited), ANJESO® (Baudax Bio, Inc.), OFIRMEV® (Mallinckrodt Pharmaceuticals), SEGLENTIS® (Kowa Pharmaceuticals America, Inc.), BARHEMSYS® (Eagle Pharmaceuticals, Inc.), TAK-951 (Takeda Pharmaceutical Company Limited), EMEND® IV and EMEND® (Merck & Co., Inc.), AKYNZEO® (Helsinn Therapeutics (U.S.), Inc.), VARUBI® (TerSera Therapeutics LLC), and FOCINVEZTM (Amneal Pharmaceuticals, LLC). The company serves markets including postoperative pain management, PONV prevention, and CINV prevention. Customers and market participants referenced include Amneal Pharmaceuticals, LLC; Baudax Bio, Inc.; Durect Corporation; Eagle Pharmaceuticals, Inc.; Fresenius Kabi USA, LLC; Helsinn Therapeutics (U.S.), Inc.; Innocoll Pharmaceuticals Limited; Kowa Pharmaceuticals America, Inc.; Mallinckrodt Pharmaceuticals; Merck & Co., Inc.; Pacira BioSciences, Inc.; Pfizer Inc.; Takeda Pharmaceutical Company Limited; and TerSera Therapeutics LLC.
Sources:
Heron Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Heron Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Heron Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
56.53 %